Your browser doesn't support javascript.
loading
A rational blueprint for the design of chemically-controlled protein switches.
Shui, Sailan; Gainza, Pablo; Scheller, Leo; Yang, Che; Kurumida, Yoichi; Rosset, Stéphane; Georgeon, Sandrine; Di Roberto, Raphaël B; Castellanos-Rueda, Rocío; Reddy, Sai T; Correia, Bruno E.
Afiliação
  • Shui S; Laboratory of Protein Design and Immunoengineering (LPDI) - STI - EPFL, Lausanne, Switzerland.
  • Gainza P; Swiss Institute of Bioinformatics (SIB), Lausanne, CH-1015, Switzerland.
  • Scheller L; Laboratory of Protein Design and Immunoengineering (LPDI) - STI - EPFL, Lausanne, Switzerland.
  • Yang C; Swiss Institute of Bioinformatics (SIB), Lausanne, CH-1015, Switzerland.
  • Kurumida Y; Laboratory of Protein Design and Immunoengineering (LPDI) - STI - EPFL, Lausanne, Switzerland.
  • Rosset S; Swiss Institute of Bioinformatics (SIB), Lausanne, CH-1015, Switzerland.
  • Georgeon S; Laboratory of Protein Design and Immunoengineering (LPDI) - STI - EPFL, Lausanne, Switzerland.
  • Di Roberto RB; Swiss Institute of Bioinformatics (SIB), Lausanne, CH-1015, Switzerland.
  • Castellanos-Rueda R; Department of Life Science, School and Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Meguro-ku, Tokyo, 152-8550, Japan.
  • Reddy ST; Laboratory of Protein Design and Immunoengineering (LPDI) - STI - EPFL, Lausanne, Switzerland.
  • Correia BE; Swiss Institute of Bioinformatics (SIB), Lausanne, CH-1015, Switzerland.
Nat Commun ; 12(1): 5754, 2021 10 01.
Article em En | MEDLINE | ID: mdl-34599176
ABSTRACT
Small-molecule responsive protein switches are crucial components to control synthetic cellular activities. However, the repertoire of small-molecule protein switches is insufficient for many applications, including those in the translational spaces, where properties such as safety, immunogenicity, drug half-life, and drug side-effects are critical. Here, we present a computational protein design strategy to repurpose drug-inhibited protein-protein interactions as OFF- and ON-switches. The designed binders and drug-receptors form chemically-disruptable heterodimers (CDH) which dissociate in the presence of small molecules. To design ON-switches, we converted the CDHs into a multi-domain architecture which we refer to as activation by inhibitor release switches (AIR) that incorporate a rationally designed drug-insensitive receptor protein. CDHs and AIRs showed excellent performance as drug responsive switches to control combinations of synthetic circuits in mammalian cells. This approach effectively expands the chemical space and logic responses in living cells and provides a blueprint to develop new ON- and OFF-switches.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Droga / Desenho Assistido por Computador / Biologia Sintética Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Droga / Desenho Assistido por Computador / Biologia Sintética Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Suíça